LEADER 05941nam 2200841Ia 450 001 9910970999303321 005 20251017110101.0 010 $a9786610183555 010 $a9780309182836 010 $a0309182832 010 $a9781280183553 010 $a1280183551 010 $a9780309566100 010 $a030956610X 035 $a(CKB)111069351128584 035 $a(SSID)ssj0000176890 035 $a(PQKBManifestationID)11165321 035 $a(PQKBTitleCode)TC0000176890 035 $a(PQKBWorkID)10209408 035 $a(PQKB)10674403 035 $a(MiAaPQ)EBC3377265 035 $a(Au-PeEL)EBL3377265 035 $a(CaPaEBR)ebr10068512 035 $a(CaONFJC)MIL18355 035 $a(OCoLC)923269360 035 $a(Perlego)4740573 035 $a(DNLM)1166764 035 $a(EXLCZ)99111069351128584 100 $a20040120d2002 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aImmunization safety review $ehepatitis B vaccine and demyelinating neurological disorders /$fKathleen Stratton, Donna A. Almario, and Marie C. McCormick, editors 205 $a1st ed. 210 $aWashington, D.C. ;$a[Great Britain] $cNational Academies Press$dc2002 215 $a1 online resource (xiv, 106 pages) $cillustrations 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$a9780309084697 311 08$a0309084695 320 $aIncludes bibliographical references (p. 85-90). 327 $aIMMUNIZATION SAFETY REVIEW -- Copyright -- Acknowledgments -- Contents -- Executive Summary -- ABSTRACT -- DEMYELINATING NEUROLOGICAL DISORDERS -- HEPATITIS B VIRAL INFECTION -- HEPATITIS B VACCINE -- EVIDENCE REVIEWED BY THE COMMITTEE -- CAUSALITY ASSESSMENT -- BIOLOGICAL MECHANISMS ASSESSMENT -- SIGNIFICANCE ASSESSMENT -- RECOMMENDATIONS FOR PUBLIC HEALTH RESPONSE -- Policy Review -- Research -- Surveillance -- Basic and Clinical Science -- Communication -- REFERENCES -- Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders -- THE CHARGE TO THE COMMITTEE -- THE STUDY PROCESS -- THE FRAMEWORK FOR SCIENTIFIC ASSESSMENT -- Causality -- Biological Mechanisms -- Terminology -- Categories of Evidence -- Published and Unpublished Data -- UNDER REVIEW: HEPATITIS B VACCINE AND DEMYELINATING NEUROLOGICAL DISORDERS -- Adverse Neurological Events -- Multiple Sclerosis -- Acute Disseminated Encephalomyelitis -- Optic Neuritis -- Transverse Myelitis -- Guillain-Barré Syndrome -- Peripheral Neuritis -- Hepatitis B Virus Infection and Hepatitis B Vaccines -- SCIENTIFIC ASSESSMENT -- Causality -- Case Reports -- Multiple Sclerosis -- Causality Argument -- First Episode of a Central Nervous System Demyelinating Disorder -- Acute Disseminated Encephalomyelitis -- Optic Neuritis -- Transverse Myelitis -- Brachial Neuritis -- Biological Mechanisms -- Immune-Mediated Processes in MS and Other Demyelinating White-Matter Diseases -- Theoretical Mechanisms for Infection-Induced Immune-Mediated Injury -- Theoretical Mechanisms for Vaccine-Induced Demyelinating Diseases -- Evidence from Animal Models for a Possible Role for Hepatitis B Vaccine in Demyelination -- Evidence from Humans -- Known Effects of Other Vaccines -- Conclusions Regarding Biological Mechanisms -- SIGNIFICANCE ASSESSMENT. 327 $aDisease Burden Associated with Multiple Sclerosis -- Hepatitis B Vaccine Safety Concerns in France -- Hepatitis B Virus Infection -- Prevention Strategies -- Acceptance of the Hepatitis B Vaccine in the United States -- Information on the Safety of the Hepatitis B Vaccine -- Conclusions -- RECOMMENDATIONS FOR PUBLIC HEALTH RESPONSE -- Policy Review -- Research -- Surveillance -- Basic and Clinical Science -- Communication -- SUMMARY -- REFERENCES -- Appendix A Committee Conclusions and Recommendations from Previous Reports -- MEASLES-MUMPS-RUBELLA VACCINE AND AUTISM -- Conclusions -- Recommendations -- Public Health Response -- Policy Review -- Research Regarding MMR and ASD -- Communications -- THIMEROSAL-CONTAINING VACCINES AND NEURODEVELOPMENTAL DISORDERS -- Conclusions -- Public Health Response Recommendations -- Policy Review and Analysis -- Public Health and Biomedical Research -- Epidemiological Research -- Clinical Research -- Basic Science Research -- MULTIPLE IMMUNIZATIONS AND IMMUNE DYSFUNCTION -- Conclusions -- Scientific Assessment -- Causality Conclusions -- Biological Mechanisms Conclusions -- Significance Assessment -- Public Health Response Recommendations -- Policy Review -- Research -- Epidemiological Research -- Basic Science and Clinical Research -- Communication -- Appendix B Public Meeting Agenda March 11, 2002 -- Appendix C Chronology of Important Events Regarding Vaccine Safety. 606 $aHepatitis B$xVaccination 606 $aHepatitis B vaccine 606 $aDemyelination$xVaccination 606 $aImmunization$xComplications 606 $aVaccination$xComplications 606 $aHepatitis B Vaccines$xadverse effects 606 $aDemyelinating Diseases$xetiology 606 $aHealth Policy 607 $aUnited States 615 0$aHepatitis B$xVaccination. 615 0$aHepatitis B vaccine. 615 0$aDemyelination$xVaccination. 615 0$aImmunization$xComplications. 615 0$aVaccination$xComplications. 615 12$aHepatitis B Vaccines$xadverse effects 615 22$aDemyelinating Diseases$xetiology 615 22$aHealth Policy 676 $a614.593 701 $aStratton$b Kathleen R$01797964 701 $aAlmario$b Donna A$01806832 701 $aMcCormick$b Marie C$01806833 712 02$aInstitute of Medicine (U.S.).$bImmunization Safety Review Committee. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910970999303321 996 $aImmunization safety review$94356225 997 $aUNINA LEADER 02774nam 2200673Ia 450 001 9910968323203321 005 20251117065140.0 010 $a0-7735-7872-2 010 $a1-282-86590-0 010 $a9786612865909 010 $a0-7735-7538-3 024 7 $a10.1515/9780773575387 035 $a(CKB)2670000000079231 035 $a(OCoLC)713186193 035 $a(CaPaEBR)ebrary10424062 035 $a(SSID)ssj0000478379 035 $a(PQKBManifestationID)11324512 035 $a(PQKBTitleCode)TC0000478379 035 $a(PQKBWorkID)10433933 035 $a(PQKB)11702899 035 $a(CEL)432883 035 $a(CaBNvSL)slc00225581 035 $a(Au-PeEL)EBL3332048 035 $a(CaPaEBR)ebr10558997 035 $a(CaONFJC)MIL286590 035 $a(OCoLC)923234051 035 $a(DE-B1597)657743 035 $a(DE-B1597)9780773575387 035 $a(Perlego)3550898 035 $a(MiAaPQ)EBC3332048 035 $a(EXLCZ)992670000000079231 100 $a20100428d2009 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHarper's team $ebehind the scenes in the Conservative rise to power /$fTom Flanagan 205 $a2nd ed. 210 $aMontreal ;$aIthaca $cMcGill-Queen's University Press$d2009 215 $a1 online resource (369 pages) $cillustrations 311 08$a0-7735-3545-4 320 $aIncludes bibliographical references and index. 327 $a1. Prelude, 1991-2001 -- 2. The Canadian Alliance Leadership Campaign, 2001-2002 -- 3. Intermission, 2002-2003 -- 4. The conservative leadership race, 2003-2004 -- 5. Getting ready, 2004 -- 6. National election, 2004 -- 7. Getting ready again, 2004-2005 -- 8. Winning the race, 2005-2006 -- 9. The ten commandments of conservative campaigning -- App. Political terminology and acronyms. 330 $aHarper's team fought four campaigns in five years: two leadership races and two national elections. Through trial and error - and determination - they learned to combine the Reform Party's strength in grassroots politics with the Progressive Conservative expertise in advertising and media relations, while simultaneously adopting the latest advances in information and communications technology. 606 $aPolitical campaigns$zCanada 606 $aPolitical leadership$zCanada 607 $aCanada$xPolitics and government$y1980- 615 0$aPolitical campaigns 615 0$aPolitical leadership 676 $a324.271094 700 $aFlanagan$b Thomas$f1944-$01810727 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910968323203321 996 $aHarper's team$94363507 997 $aUNINA